# Evaluation of SAR408701 in Patients With Advanced Solid Tumors

> **NCT02187848** · PHASE1 · TERMINATED · sponsor: **Sanofi** · enrollment: 254 (actual)

## Conditions studied

- Neoplasm Malignant

## Interventions

- **DRUG:** SAR408701

## Key facts

- **NCT ID:** NCT02187848
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07-23
- **Primary completion:** 2020-11-10
- **Final completion:** 2024-11-19
- **Target enrollment:** 254 (ACTUAL)
- **Why stopped:** Sponsor decision, The decision is not related to any safety concern.
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02187848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02187848, "Evaluation of SAR408701 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02187848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*